Three weeks after Bruker Biosciences said a rebound in its mass spectrometry division helped the company post a 9-percent increase in total revenue during its second quarter, a research note by an investment bank analyst cautioned that the company’s mass-spec business could be hurt by bigger competitors.
 
The note by UBS analyst Derik De Bruin came as the investment firm downgraded Bruker’s stock to “neutral” from “buy” while maintaining a $7 target price on the shares.
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Publication of He Jiankui's work on gene-edited infants would raise ethical concerns for journals, Wired and others report.

The New York Times reports that evidence linking trauma in one generation to epigenetic effects that influence subsequent generations may be overstated.

ScienceInsider reports that US National Institutes of Health researchers were told in the fall they could not obtain new human fetal tissue.

In PNAS this week: skin pigmentation evolution among KhoeSan, biomarkers for dengue virus progression, and more.